Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment

Title: Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment

Volume: 16 Issue: 36

Author(s): Ning Liu, Hao Fang, Yanling Li and Wenfang Xu

Affiliation:

Keywords: Cell cycle, G1-phase, cyclin-dependent kinases, CDK4, tumor, selective inhibitors, anti-cancer agents

Abstract: It is well known that cyclins and cyclin-dependent kinases (CDKs) play essential roles in regulation of the cell cycle. In past two decades, the scientific researches suggest that the cyclin D1/ CDK4 complex is a key regulator of the transition through the G1 phase of the cell cycle. Moreover, deregulation of the cyclin D /CDK4 pathway has been identified in multiple tumor types. Thus, CDK4 is a genetically validated therapeutic target; hence, there has been a surge of interests in finding selective CDK4 inhibitors as anti-cancer agents. This review will give the recent progress in the studies of structure, functions of CDK4 and highly selective and potent CDK4 inhibitors.

Cite this article as:

Liu Ning, Fang Hao, Li Yanling and Xu Wenfang, Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment, Current Medicinal Chemistry 2009; 16 (36) . https://dx.doi.org/10.2174/092986709789909611